AlphaValue/Baader Europe Lowers Price Target on Alcon, Maintains Add Recommendation
UBS Sticks to Their Buy Rating for Alcon (ALC)
Kepler Capital Reaffirms Their Sell Rating on Alcon (ALC)
Alcon Analyst Ratings
Oppenheimer Upgrades Alcon to Outperform From Perform, $103 Price Target
Baird Adjusts Price Target on Alcon to $104 From $95, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), ScPharmaceuticals (SCPH) and Ascendis Pharma (ASND)
Needham: Maintaining the Alcon (ALC.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $98.00 to $101.00.
Alcon Analyst Ratings
Needham Maintains Buy on Alcon, Raises Price Target to $101
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Annexon Biosciences (ANNX) and Ascendis Pharma (ASND)
Needham: Reiterates Alcon (ALC.US) rating and adjusted from buy to buy rating, target price is $98.00.
Alcon Analyst Ratings
UBS Remains a Buy on Alcon (ALC)
Alcon Q1 2024: Strong Earnings Growth & Operational Efficiency Drive Buy Rating
Alcon's Solid Performance and Growth Momentum Justify Buy Rating Despite FX Headwinds
Alcon's Growth Trajectory: Positive Survey Insights and Product Launches Drive Buy Rating
Alcon Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Iradimed (IRMD)
Alcon Analyst Ratings